Tag AMZN

Tech giant Amazon (NASDAQ: AMZN) smashed expectations last quarter, showing it made big improvements in profitability. Amazon's margins are stronger, especially in its largest segment. In the midst of Amazon's supersized growth during the pandemic, the company, along with others in the tech industry, hired staff aggressively...

These Warren Buffett stocks can help investors position their portfolios for success in the coming bull market...

No one knows where the markets are headed this year or next, but investors don't have to time the market to be successful. This is why investors should consider buying shares of Amazon (NASDAQ: AMZN) and Tesla (NASDAQ: TSLA). Amazon's growth in online retail and cloud services delivered incredible returns to investors over the last decade...

Amidst a sharp rise in long-duration treasury yields, Amazon stock declined by ~7% from its post-earnings high of ~$144. Learn why I continue to rate AMZN stock a Buy...

Investment management company Vulcan Value Partners recently released its second-quarter 2023 investor letter. A copy of the same can be downloaded here. The firm has five strategies, and all gained positive absolute returns in the second quarter. The fund’s Large Cap Composite returned 10.0% net of fees and expenses, the Small Cap Composite returned 4.4% net, the Focus […]...

In this piece, we will take a look at the stocks that Ken Fisher and corporate insiders are betting on. If you want to skip our introduction to insider trading and Mr. Fisher then skip to Ken Fisher’s and Insiders’ 5 Stock Picks. Insider trading is often thought to be illegal. The most commonly understood […]...

Hollywood studios will once again meet with striking writers — but the impact of the prolonged work stoppage is only just beginning...

Blue Shield of California shocked a lot of people when it announced it was going to drop CVS Health (CVS) as its main pharmacy benefit manager (PBM) and instead go with companies like Amazon Pharmacy (AMZN) and Mark Cuban's Cost Plus Drugs. Blue Shield of California CEO Paul Markovich tells Yahoo Finance Live the current system is designed to "maximize the profit of the participants as opposed to the quality, cost effectiveness, and convenience of consumers." Markovich says "PBMs, as they exist, clearly need to change and change pretty fundamentally," adding that "incentives and all of the behaviors that come along with it, make drugs highly and unsustainably inflationary."...